Organogenesis posts record Q3 revenue of $150.5M, raises FY2025 guidance

Organogenesis Holdings Inc.

2025-Q3 EPS reported -$0.12 revenue$338,562,000

Net product revenue $150.5M (+31% YoY); Advanced Wound Care $141.5M (+31%), Surgical & Sports Med $9.0M (+25%).
Net income $21.6M ($0.11 diluted EPS) vs $12.3M ($0.09) YoY; adjusted net income $23.2M.
Adjusted EBITDA $30.1M vs $13.4M YoY; operating income $20.7M vs $6.2M.
FY2025 revenue guidance raised to $500-525M (4-9% YoY); Adj. net income guided $21.5-38.4M.
Cash $64.4M, no debt; cash down from $136.2M due to operations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.